Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis

Learn more about:
Related Clinical Trial
Radiofrequency Ablation of Adenomyosis Determination of the Incidence of Endometriosis and or Adenomyosis in Patients Diagnosed With Polycystic Ovary Syndrome, or the Incidence of Polycystic Ovary Syndrome in Patients Diagnosed With Endometriosis and or Adenomyosis The Effect of Adenomoyosis on Pregnancy Outcomes Observational Study of Patients Suffering From Endometriosis and Adenomyosis Factors Associated With Adenomyosis and a Clinical Scoring System for the Diagnosis Quality of Life After Hysterectomy (AdenoQOL) Low Molecular Weight Heparin on the Adenomyosis Patients’IVF-ET Outcome Diagnosis of Adenomyosis Using Ultrasound, Elastography and MRI Clinical and Molecular Study of Endometriosis and Adenomyosis Surgical Success After Laparoscopic vs Abdominal Hysterectomy Electronic Catheter Stethoscope Ovarian Reserve Modification After Lps Hysterectomy With Bilateral Salpingectomy Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? Single-port Access Laparoscopic-assisted Vaginal Hysterectomy Uterine Artery Embolization for Symptomatic Fibroids Oxytocin in MRI-HIFU To Compare to 2-channel and Multiple-channel Single Port Laparoscopic-assisted Vaginal Hysterectomy Effect of Addition of Steroids on Duration of Analgesia Paracervical Block in Laparoscopic Hysterectomy Use of Dexamethasone in Uterine Artery Embolization Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU) Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS) Dienogest for Treatment of Adenomyotic Uteri Health-Related QoL Among Women Receiving Hysterectomy in NTUH Development and Validation of EHP-30 (Hong Kong Chinese Version) for Patients With Endometriosis and Adenomyosis Adenomyosis and Ulipristal Acetate Efficacy of Acupuncture on Chronic Pelvic Pain in Women With Endometriosis or Adenomyosis LNG-IUS for Treatment of Dysmenorrhea Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis Adenomyosis: Genomic Mechanisms and Biological Response What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography Comparing Efficacy of Microwave vs Embolization Treatment for Adenomyosis Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis A Prospective Study of Diagnostic Accuracy of Ultrasound Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis A Multi-omics Study of Adenomyosis Norwegian Adenomyosis Study II: Gene Expression Profiling of Adenomyosis Levonorgestrel Intrauterine System and Adenomyosis Validation of the Adenomyosis Calculator Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri Modified Downregulation for Women With Adenomyosis of the Uterus Prior to Frozen-thawed Embryo Transfer. New Inflammation Markers for Distinguishing Uterine Adenomyosis and Leiomyoma The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms High-intensity Focused Ultrasound in Treatment of Uterine Adenomyosis Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis Norwegian Adenomyosis Study III: Peristalsis Histopathological Diagnosis of Adenomyosis Norwegian Adenomyosis Study I Vaginal Bromocriptine for Treatment of Adenomyosis Levonorgestrel-releasing Intrauterine System for the Treatment of Symptomatic Adenomyosis

Brief Title

Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis

Official Title

Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis

Brief Summary

      Endometriosis (including adenomyosis) is one of the most common gynecological diseases among
      women of childbearing age. Common symptoms such as menstrual pain, excessive menstrual flow,
      infertility, chronic lower abdominal pain, and painful intercourse. According to the
      literature statistics, the prevalence of endometriosis in women of childbearing age is about
      10-20%, while the prevalence of adenomyosis is about 5%. Traditional medical treatments
      include hormones (danazol, gestrinone, oral lutein). Oral contraceptive, there is a
      Gonadotropin-releasing hormone agonist in the injection form, and a levonorgestrel-releasing
      intrauterine system in the intrauterine administration system. The choice of drugs has many
      influencing factors, such as the severity of endometriosis in patients (according to the
      classification of the American Society for Reproductive Medicine), the need for fertility,
      the convenience of drug use, and the patient's tolerance to drug side effects. Surgery is
      also one of the treatment options for endometriosis and adenomyosis, including traditional
      open or minimally invasive endoscopic ovarian cyst resection, oophorectomy, and lesion
      resection; adenomyosis surgery includes traditional methods Open abdominal, transvaginal or
      minimally invasive endoscopic hysterectomy, conservative uterine sparing adenomyomectomy and
      cytoreduction surgery (partial adenomyomectomy). For endometriosis, the common treatment
      consensus of obstetricians and gynecologists is to follow the surgical treatment of the
      lesions and then follow-up medication. For women with adenomyosis, if they have completed the
      birth, it is recommended to have a total hysterectomy, so that there is no recurrence. The
      possibility. However, for women who have not completed birth, conservative uterine
      preservation surgery is performed. According to research statistics, endometriosis or
      adenomyosis does not receive follow-up medical treatment after completion of surgical
      treatment, there is a high probability of recurrence, but the side effects caused by drugs
      will also affect the patient's compliance with medication.The Department of Women's Medicine
      of the hospital has a wealth of experience in the treatment of endometriosis and adenomyosis.
      Each year, about 500 cases of endometriosis (including adenomyosis) are performed. This study
      was designed to analyze the differences in prognosis and recurrence of patients with
      endometriosis and adenomyosis after receiving various surgical and medical treatments.
    

Detailed Description

      The main purpose: to analyze the prognosis and treatment effect of endometriosis and
      adenomyosis after surgery and drug treatment.

      Secondary objective: Analysis of endometriosis and adenomyosis after surgery and medication,
      the patient's assessment of drug side effects.
    


Study Type

Observational


Primary Outcome

Pain before and after surgery

Secondary Outcome

 Hemoglobin

Condition

Endometriosis

Intervention

Leuprorelin

Study Arms / Comparison Groups

 Gonadotropin-releasing hormone agonist treatment
Description:  Endometriosis post-operative Gonadotropin-releasing hormone agonist treatment

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

5000

Start Date

January 1, 2005

Completion Date

October 18, 2018

Primary Completion Date

December 31, 2015

Eligibility Criteria

        Inclusion Criteria:

          -  Patients who underwent endometriosis or adenomyosis-related surgery in the
             investigator's hospital from 2005/01/01 to 2018/12/31, and received follow-up
             medication.

        Exclusion Criteria:

          -  None
      

Gender

Female

Ages

N/A - N/A

Accepts Healthy Volunteers

No

Contacts

Peng-Hui Wang, MD, PhD, , 

Location Countries

Taiwan

Location Countries

Taiwan

Administrative Informations


NCT ID

NCT03778359

Organization ID

2017-10-012AC


Responsible Party

Sponsor

Study Sponsor

Taipei Veterans General Hospital, Taiwan


Study Sponsor

Peng-Hui Wang, MD, PhD, Study Chair, [email protected]


Verification Date

December 2018